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SputumGlobal tuberculosis (TB) control and eradication is hampered by the unavailability of simple, rapid and affordable
diagnostic tests deployable at low infrastructuremicroscopy centers.We have developed and evaluated the per-
formance of a nucleic acid ampliﬁcation test for detection ofMycobacterium tuberculosis (MTB), theNWU-TB test,
in clinical sputum specimens from 306 patients with suspected pulmonary tuberculosis. The test involves spu-
tum sample processing using a Lyser device within 7 min, followed by rapid multiplex-PCR on a fast thermal
cycler within 25 min, and amplicon resolution on agarose gel electrophoresis. Samples were also examined for
presence of MTB using smear microscopy, GeneXpert and MGIT culture. Results were assessed in comparison
to a MGIT culture as gold standard. Of the 306 patients, 174 had a previous TB history or already on treatment,
and 132 were TB naïve cases. The NWU-TB system was found to have an overall sensitivity and speciﬁcity of
80.8% (95% CI: 75–85.7) and 75.6% (95% CI: 64.9–84.4) respectively, in comparison to 85.3% (95% CI: 79.9–
89.6) and 73.2% (95% CI: 62.2–82.4) respectively for GeneXpert; and 62.1% (95% CI: 55.3–68.4) and 56.1% (95%
CI: 44.7–67) respectively for smear microscopy. The study has shown that the NWU-TB system allows detection
of TB in less than two hours and can be utilized at low infrastructure sites to provide quick and accurate diagnosis
at a very low cost.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One hundred and thirty three years after Robert Koch recognized
Mycobacterium tuberculosis (MTB) as the causative agent of tuberculosis
(TB), it still poses an enormous global public health burden today (Koch,
1882). It is estimated that a third of the world's population, is infected
with MTB, but most never develop active TB disease (Sudre et al.,
1992). This is not the case, however, for persons living with human
immunodeﬁciency virus (HIV) who contract TB infection. People with
HIV-infection are 26 to 31 times more likely to become sick with TB in
a given year compared to HIV-negative persons (World Health
Organization, 2014). Worldwide, an estimated one-third of people
living with HIV/AIDS are co-infected with TB. In 2013, there were an
estimated 9.0 million new cases of TB (13% co-infected with HIV) and
1.4 million TB deaths globally (World Health Organization, 2014). In
the same year, of the 27 countries that reported their multi-drug resis-
tant tuberculosis (MDR-TB) data, the cases reached 450,000; of these,
170,000 people died (World Health Organization, 2014).tingwende),
. This is an open access article underSouth Africa is home to the highest number (6.1 million individuals)
of people living with HIV/AIDS (UNAIDS, 2013). This has led to an in-
crease in the number of TB cases over the past decade, with the estimat-
ed TB incidence approaching 715/100,000 (World Health Organization,
2014). HIV-positive patients with smear-negative pulmonary TB
(SN-PTB) are generally more severely immunosuppressed than those
with smear-positive TB. Outcomes for them are poorer, especially
when drug regimens do not contain rifampicin (Corbett et al., 2003).
In a study of HIV-positive TB patients in Khayelitsha, South Africa, 49%
of patients on TB treatment had negative smears on direct microscopy
but their sputum cultures were positive (Coetzee et al., 2004). This
makes smear microscopy, the most commonly used TB diagnostic test
at low infrastructure sites, unreliable in Sub-Saharan Africa where HIV
prevalence is high.
Global partnerships to improve disease diagnosis and appropriate
treatment are a priority to prevent further global spread of TB. Compli-
cations due to HIV co-infection and emergence of drug resistant MTB
strains seek to erode the gains that have been made so far to eradicate
TB globally (Sharma and Mohan, 2006; Small and Pai, 2010). One
critical impediment in the global ﬁght against TB is the lack of rapid, af-
fordable and effective diagnostics tests that can be performed at low-
infrastructure sites, right at the doorsteps of most of the vulnerable
communities (Urdea et al., 2006). Without better diagnostic tools forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Sequences of primers used in multiplex PCR.
Primer name Sequence fragment
Pab f 5′-ACC ACC GAG CGG TTC GCC TGA-3′ 419 bp
Pab r 5′-GAT CTG CGG GTC GTC CCA GGT-3′
IS1 5′-CCT GCG AGC GTA GGC GT-3′ 123 bp
IS2 5′-CTC GTC CAG CGC CGC TTC GG-3′
MPB1 5′-TCC GCT GCC AGT CGT CTT CC-3′ 240 bp
MPB2 5′-GTC CTC GCG AGT CTA GGC CA-3′
Fig. 1. Lyser device and lysis microreactor used during cell lysis step in the NWU-TB
system.
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sion will not be interrupted, mortality will not be checked, and TB will
not be controlled especially in areas where HIV infection is prevalent.
Culture remains the gold standard for TB diagnosis despite its long
turnaround time of between 2 and 6 weeks due to slow mycobacterial
growth (Pai et al., 2004a). Ziehl-Neelsen sputum smear microscopy
(SSM) is the most widely method at the primary level in Sub-Saharan
Africa (SSA) due to its low installation and per sample costs. However
it has poor and variable sensitivity (20–60%) especially in HIV/TB
co-infected patients, and cannot distinguish MTB from other non-
tuberculosis mycobacteria (NTM) (Pai et al., 2004b; Steingart et al.,
2006). The costs to patients associated with multiple visits to clinics to
provide specimens before treatment starts are oftentimes prohibitive
and cause infectious individuals to drop out of the treatment program.
Recently, GeneXpert, an automated user-friendly real-time polymerase
chain reaction (PCR) assay able to simultaneously detectM. tuberculosis
(MTB) and rifampicin resistance has beenwidely deployed and adopted
in South Africa (Lawn et al., 2013; Nicol et al., 2011). It has a total assay
time (TAT) of 2 h, high sensitivity and speciﬁcity in sputum samples but
the test is expensive with a current unsubsidized cost of US$16 per test,
which the majority of people in Africa cannot afford. Given the back-
ground of these concerns, current research must focus on simplifying
test protocols, decreasing cost and improving accuracy. Moreover, for
sustainable solutions to the TB/HIV burden to become a reality, Africa
as the greatest bearer of that burden should be part of thewhole supply
chain equation, right fromproduct development to patient use.Without
building and supporting diagnostic tests, development initiatives in
Africa to solve diseases particular to that region, the list of manageable
diseases that continues to unnecessarily kill millions of people yearly,
is sure to keep growing uncurbed.
Several studies have documented the risk of mycobacterial infection
of people working in diagnostic and research laboratories (Garber et al.,
2003; Grist and Emslie, 1985; Miller et al., 1987; Muller, 1988). In spite
of current knowledge on precautions and safety guidelines in TB labora-
tories, in 2003 TB conversion among healthcare workers (HCWs) in
New York ranged from 2 to 6.6% (Garber et al., 2003). Some reports
even suggest underreporting of the cases due to the social stigma at-
tached and slow disease progression, whichmay result in HCW retiring
before becoming symptomatic (Collins and Kennedy, 1999; Pike, 1976,
1979). Manipulation of liquid clinical specimens involves generation of
infectious aerosols and exposure to these aerosols represents one of the
most serious hazards encountered in the laboratory (Miller et al., 1987;
Muller, 1988). Any new TB diagnosis systemmust have a proven safety
proﬁle to the health workers that operate it.
In an effort to have a simple, affordable, rapid and safe TB diagnostic
system, a simple DNA diagnostic system forMTB detection (herein after
referred to asNWU-TB system)wasdeveloped,which can be readily ap-
plied to some other diseases. This molecular based system aims to pos-
sess the high accuracy associatedwith othermolecular based diagnostic
systems, butwith the low cost structure of SSM. It is envisaged that such
a system may replace SSM in SSA. However, before deployment of the
NWU-TB system, there is a need to conduct a number of independentstudies to evaluate its performance using clinical samples. In the present
studywe describe and evaluate the performance and biosafety of NWU-
TB system in clinical sputum samples.
2. Materials and methods
Specimen collection, SSM, MGIT culture, and Xpert MTB/Rif were
performed by independent staff at Orkney-Westvaal Hospital, North
West Province, South Africa. The Orkney-Westvaal Hospital is wholly
owned and privately operated by AngloGold Ashanti to treat its gold
miners. The NWU-TB system development and testing was performed
at the North-West University, Potchefstroom Campus, South Africa.
2.1. Study population and specimens
Thiswas a single site, blinded, prospective study conducted between
January 2013 and October 2014 to evaluate the performance of the
NWU-TB system in patients with suspected pulmonary TB in compari-
son to standard tests. Sputum samples were obtained under the super-
vision of trained nurses frompresumptive TB patients on routine visit to
the hospital. Standard TB tests (SSM, MGIT culture, GeneXpert) were
performed on all patients, however, due to the large sputum volume
required to perform all three tests it was not possible to perform
GeneXpert for some patients. Left-over sputum samples after standard
TB tests were frozen at−20 °C and transferred to the North-West Uni-
versity every fortnightwhere theywere stored under similar conditions
until testing. To avoid bias, sputum samples from both TB treatment
naive individuals and those at various anti-TB treatment stages were
included in the study. Relevant patient information [including the TB
patient history (for reinfection cases)] was only received at the data
analysis stage. Sample storage time at the North-West University
ranged from 2 weeks to 1 year before performing the indicator test.
HIV testingwas performed as part of routine care for consenting pa-
tients according to standard guidelines (World Health Organization,
2004).
2.2. Reference standard tests
2.2.1. Sputum smear microscopy (SSM)
Two drops of NaOH-NALC decontaminated sample pellet were used
for smear microscopy (ZN staining), according to standard protocol
(World Health Organization, 1998). The grading of the AFB results was
done in accordance with the WHO/International Union Against Tuber-
culosis and Lung Disease guidelines and scored as “0” for absence of
AFB, scanty 1–9, 1+, 2+, or 3+ (World Health Organization, 1998).
2.2.2. MGIT culture
Samples were processed according to the manufacturers' guidelines
for MGIT 960 cultures (Becton Dickinson and Company, 2013). Brieﬂy,
N-Acetyl-L-cysteine–1% sodium hydroxide (ﬁnal concentration after
mixing with the specimen) was used to decontaminate the sputum
sample. Specimens were concentrated by centrifugation at 3000 ×g,
and pellets were resuspended in 0.5 ml of sterile phosphate buffer.
0.5 ml of the processed samples was inoculated into pre-prepared my-
cobacterial growth indicator tubes (MGITs) (Becton Dickinson, Sparks,
Maryland), and incubated at 37 °C for 6 weeks using the BACTEC
Fig. 2.Multiplex PCR ampliﬁcation of IS6110 (123 bp),MPT64 (240 bp) and protein antigen b (419 bp). L— 100 bpmarker; neg— negative control; pos— positive control; and S1 to S10—
patient sputum samples.
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a positive result. Culture was considered negative after six weeks if the
instrument did not detect mycobacterial growth except in cases where
AFB smear was positive: then cultures were held for a total of 8 weeks.
Qualitative conﬁrmation of Mycobacterium tuberculosis complex
(MTBC) in culture positive MGIT tubes was performed using the MGIT
BDMGIT TBc Identiﬁcation Test (TBc ID) (Becton, Dickinson & Company,
Sparks, MD, USA) according to the manufacturers' instructions (BD
Diagnostics, 2013).
2.2.3. GeneXpert
GeneXpert was performed according to the manufacturer's standard
operating procedure (SOP) (Cepheid, USA). Brieﬂy, in a 2:1 ratio, the sam-
ple reagent (Cepheid) was mixed with NaOH–NALC decontaminated
sputum sample and incubated at room temperature for 15min. Twomil-
liliters of the mixture were transferred into an Xpert MTB/Rif cartridge
and inserted into the instrument. The instrument automatically called a
result.
2.2.4. NWU-TB
The NWU-TB system consists of three sequential steps; cell lysis
within 7 min using a Lyser device, followed by Multiplex-PCR within
25min and amplicon visualization on an agarose gel. Stored frozen spu-
tumsampleswere thawed overnight at 4 °C, 250 μl of samplewasmixed
with an equal volume of lysis buffer [of 20 mM DTT (Dithiothreitol,
Sigma-Aldrich, Inc., St. Louis, MO) and 20× TE (Tris–EDTA, Sigma-
Aldrich, Inc., St. Louis, MO)] in a lysis microreactor (LMR) (Fig. 1). The
LMR was placed on a preset (115 °C and 5000 rpm) Lyser device
(Fig. 1) for 7 min. Bacterial cell lysis is concurrently achieved through
chemical, thermal and mechanical means (Grobler et al., 2012). 4 μl of
lysate was used in the subsequent Multiplex-PCR (M-PCR) step. Each
M-PCR reaction in a ﬁnal volume of 20 μl contained 0.4 mg/ml BSA
(Ambion, Foster City, CA, USA), 200 mM of each dNTP, 3.5 mMFig. 3. Patient ﬂow, showing the two arms for datMgSO4, 1 U KOD Hotstart DNA polymerase in appropriate 10× buffer
(Novagen, San Diego, USA), and 200 nM of each of the previously de-
scribed primers as shown in Table 1 (Kusum et al., 2011). Themultiplex
primers used target three separate genes in theM. tuberculosis complex
genome which are IS6110, protein antigen b and MPB 64. M-PCR was
performed on a Philisa rapid thermal cycler (Streck Inc., Omaha, NE)
using the following protocol: Initial enzyme activation at 95 °C for
120 s, followed by 40 cycles of 95 °C for 10 s, 66 °C for 15 s and 72 °C
for 6 s, and a ﬁnal extension step at 72 °C for 120 s. PCR products were
resolved by electrophoresis (Fig. 2) on a 2% agarose gel stained with
gelred nucleic acid stain (Biotium, Hayward, CA, USA). Any specimen
yielding a negative result in the NWU-TB system was re-tested if there
was sufﬁcient residual sputum and the latter result was considered in
the analysis.
2.2.5. Biosafety evaluation of NWU-TB cell lysis step
MTB clinical isolates were inoculated into 12 MGIT tubes and incu-
bated using the BACTEC-MGIT 960 automated culture system until the
instrument automatically called a positive result, which occurred on
day 12. This has been reported to correspond with approximately 10
6 CFU/ml (Castan et al., 2014). Tween-80 (0.05%) was added to all
MGIT tubes before transferring the contents into separate 15 ml sterile
conical tubes followed by three successive rounds of vortexing each
lasting about 7 min to declump the mycobacteria.
Conﬁrmed smear negative-culture negative samples from two indi-
viduals were pooled together and used as diluent in preparing 10 fold
serial dilutions (106, 105, 104, 103, 102, and 101 CFU/ml) in quintuples.
For each dilution, the contents of 3 of the 5 tubes were subjected to
lysis, and the other two tubeswere not lysed (used as positive controls).
Lysis was performed as per standard procedure in the NWU-TB system
(described above). Pre-prepared MGIT tubes were inoculated with
500 μl of appropriate sample (dilutions described above) and incubated
using the BACTEC-MGIT-960 for 42 days.a analyses, namely the Cohort and Subgroup.
Table 2
Demographic information and microbiological characteristics of subgroup and cohort in
the analysis arms.
Subgroup Cohort
No. of TB suspects 132 306
Median age in years (95% CI) 43.9 (42.4–45.4) 46.0 (39.0–51.0)
HIV prevalence (n) % (64/85) 75.3 (122/160) 73.7
Sex
Male n (%) 127 (95.5) 295 (96.4)
Female n (%) 5 (4.5) 11 (3.6)
Race
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Accuracy measures (sensitivity, speciﬁcity, positive and negative
predictive values) of the evaluated tests for M. tuberculosis detection
were determined usingMGIT culture as the gold standard. Only samples
that had all smear, culture, Xpert MTB/Rif, and NWU-TB system results
were included in the analysis. Statistical analyses were performed
using STATA 11 (StataCorp, College Station, TX, USA). Due to the high
frequency of TB re-infections (28.4%) in our cohort, a subgroup analysis
(herein after referred to as subgroup) of patients with no known TB his-
tory and treatment TB naive was carried out.Black n (%) 132 (100) 306 (100)
Previous TB history n (%) 0 (0) 174 (56.9)
Smear and culture grading
Smear+ culture+ n (%) 66 (50.0) 139 (45.4)
Smear− Culture+ n (%) 39 (29.5) 85 (27.7)
Smear+ Culture− n (%) 20 (15.2) 36 (11.8)
Smear− Culture− n (%) 7 (5.3) 46 (15.0)2.2.7. Ethics
This study was approved by the North-West University Research
Ethics Committee under ethics number: NWU-00005-11-A5. NWU-TB
system results were not used in clinical decision making.3. Results
3.1. Patient population
548 sputumsampleswere supplied to theNorth-WestUniversity re-
search team by Orkney-Westvaal Hospital over the indicated period;
however for various reasons such as inadequate sample volumes to per-
formGeneXpert test or culture contamination, only 306 samples had re-
sults for all four tests and were thus included in the analysis. After
unblinding and considering TB patient history, two data analysis arms
were decided upon. Of the 306 (referred to as cohort) samples, 132
met the subgroup inclusion criteria as highlighted in the statistical anal-
ysis section (Fig. 3).
General demographic and microbiological characteristics of the
study population are shown in Table 2. The median age of the cohort
and subgroup was 43.9 and 46.0 years respectively. The cohort is pre-
dominantlymale (96.4%), which is above the 2:1 (male: female) gender
inequality seen in adult TB. This is because the hospital caters only for
miners, who are mainly males. Of the 160 patients tested for HIV in
the cohort, 122 (73.7% prevalence) were positive, which is similar to
75.3% in the subgroup. Based on SSM and culture classiﬁcation, smear
positive-culture positives were the highest: 50% and 45.4% in the sub-
group and cohort respectively.Table 3
Performance of SSM, GeneXpert, and NWU-TB system against MGIT culture as gold
standard.
Parameter SSM GeneXpert NWU-TB
Sensitivity % (95% CI) 62.9 (52.9–72.1) 83.8 (75.3–90.3) 87.6 (79.8–93.2)
Speciﬁcity % (95% CI) 74.1 (53.7–88.9) 70.4 (49.8–86.2) 88.9 (70.8–97.6)
PPV % (95% CI) 90.4 (81.2–96.1) 91.7 (84.2–96.3) 96.8 (91–99.3)
NPV % (95% CI) 33.9 (22.1–47.4) 52.8 (35.5–69.6) 64.9 (47.5–79.8)
DOR 4.84 (1.91–12.2) 12.3 (4.7–32.1) 56.6 (15.6–201)3.2. Performance of NWU-TB in the individuals with no TB history (referred
to as subgroup analysis)
When analyzed against MGIT culture as gold standard, the sensitiv-
ities of SSM, GeneXpert and NWU-TB were 62.9% [95% CI: 52.9, 72.1];
83.3% [95% CI: 75.3, 90.3]; and 87.6% [95% CI: 79.8, 93.2], respectively
(Table 3). NWU-TB was more sensitive than SSM (p = 0.001) and had
comparable sensitivity to GeneXpert (p = 0.135). The speciﬁcity of
both GeneXpert and NWU-TB was signiﬁcantly lower than expected
as reported in other studies.
Positive predictive values (PPV), negative predictive values (NPV),
and Diagnostic odds ratio (DOR) of SSM, GeneXpert, and NWU-TB are
provided in Table 3. In all the indicators NWU-TB is better than SSM
and comparable to GeneXpert.
The sensitivity of NWU-TB in the paucibacillary smear negative-
culture positive group was 76.1% [95% CI: 60.7, 88.9]. Interestingly, in
the culture negative group, 13 samples had positive results with the
other 3 tests contributing to the unexpected high sensitivities for both
NWU-TB and GeneXpert in smear positive-culture negative and smear
negative-culture negative groups (Table 4). This raises a number of
questions as to the sensitivity of culture in a high TB prevalence setting
(mining/prisons) and the impact on diagnostic test evaluation in such a
cohort.3.3. Performance of NWU-TB in cohort analysis
The performance of NWU-TB againstMGIT culture performed on the
same sputum samples is shown in Table 5 alongside outcomes for SSM
and GeneXpert. The overall sensitivity in NWU-TB at 95% conﬁdence in-
terval was 80.8% (75%–85.7%). This was lower than GeneXpert with a
sensitivity of 85.3% (79.9%–89.6%) (p = 0.026), but better than SSM
62.1% (55.3%–68.4%) (p=0.001). Speciﬁcity of NWU-TB andGeneXpert
was still lower than expected as in the subgroup analysis.
For the NWU-TB system, when stratiﬁed by HIV status, there was
better sensitivity in the HIV negative group 86.8% (71.9%–95.6%) com-
pared to the HIV positive group 78.7% (70.4%–85.6%), though not statis-
tically signiﬁcant (p = 0.190). Similar results with no statistical
signiﬁcance (p = 0.519) were also observed with GeneXpert 89.5%
(75.2%–92.7%) in the HIV seronegative group compared to 86.1%
(78.6–91.7%) in the HIV seropositive group.
3.4. Frequency of non-tuberculosis mycobacteria
Though this was not part of the initial study design, the high fre-
quency of non-tuberculosismycobacteria (NTM) (Table 6) in our cohort
warrants reporting on.
3.5. Biosafety evaluation
No growthwas observed in any of the lysed cultures, independent of
the concentration after 42 days of MGIT culture (Fig. 4). There was
growth in all positive controls and time to positivity was inversely pro-
portional to starting mycobacteria concentration.
4. Discussion
Diagnostics tests are important decision support tools for physicians
and nurses in deciding on the most appropriate drug regimens for var-
ious diseases. Toward this end, clinicians need rapid, accurate, afford-
able and accessible diagnostic tests before prescribing appropriate
medication. Despite the recent upsurge in the number of MTB detection
Table 6
Frequencies of non-tuberculosis mycobacteria found in the cohort.
NTM Frequency Growth rate
M. abscessus 1 Rapid grower
M. avium 24 Slow grower
M. chelonei 3 Rapid grower
M. fortuitum complex 4 Rapid grower
M. intracellulare 1 Slow grower
M. kansasii 25 Slow grower
M. Simiae 1 Slow grower
Table 4
Sensitivities of SSM, GeneXpert, and NWU-TB in various SSM and culture result groups.
Smear–culture grade GeneXpert % (95% CI) NWU-TB % (95% CI)
Smear-positive, culture-positive 96.7 (89.5–99.6) 93.9 (85.2–98.3)
Smear-negative, culture-positive 61.5 (44.6–76.6) 76.1 (60.7–88.9)
Smear-positive, culture-negative 15.0 (3.21–37.9) 0.0 (0.0–16.8)
Smear-negative, culture-negative 71.4 (29.4–96.3) 42.9 (9.9–81.6)
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tings are still a high priority. Urdea et al. (2006) states that a rapid TB di-
agnostic test requiring no laboratory infrastructure, with at least 85%
pooled sensitivity for smear-positive and smear-negatives cases, and
97% speciﬁcity, could save approximately 400,000 lives annually
(Urdea et al., 2006). However, even the most promising diagnostic
test will have only limited impact if it does not reach the patients who
need it. A real-world evaluation of one such systemunder development,
aiming to address those concerns and more especially the affordability
aspect has been conducted.
The NWU-TB system performance in the both the subgroup and co-
hort analysis is comparable to that of GeneXpert, which is also a molec-
ular based system. The observed sensitivity of GeneXpert in this study is
within the range previously reported in similar studies conducted in
other high HIV prevalence settings (Chang et al., 2012; Scott et al.,
2011; Theron et al., 2011). However, the speciﬁcity is lower than that re-
ported in literature: From our data we observed 13 samples in which all
3 of the other tests were positive except culture. Marlowe et al. (2011)
also reported true positive results with the GeneXpert system in
culture-negative clinical specimens. Furthermore, although, MGIT
culture is considered the current gold standard for MTB diagnosis, it is
not 100% sensitive itself, thus some of the MGIT culture negatives are
likely to be true positives (McCarthy et al., 2012; Muchwa et al.,
2012). Culture negative active TB has also been shown to be character-
ized by clinical disease and highly suggestive Chest X-ray (CXR) abnor-
malities (Maher, 2009).
The high prevalence of NTMs in our cohort is bound to have contrib-
uted to the poor speciﬁcity, as the NTM-positive participants possibly
also hadM. tuberculosis, which might have been outcompeted in MGIT
culture (Dinnes et al., 2007; Ssengooba et al., 2014). The usefulness of
GeneXpert in culture negative samples, especially in HIV seropositive
patients, warrants urgent investigation in order to address the increas-
ingly observed MGIT culture limitations in this group. Future studies
with more robust identiﬁcation methods such as 16S rDNA sequenceTable 5
Performance outcomes of SSM, GeneXpert, and NWU-TB stratiﬁed by HIV status, against
MGIT culture as gold standard in the cohort.
Parameter SSM % (95% CI) GeneXpert % (95% CI) NWU-TB % (95% CI)
Sensitivity
Cohort (n = 306) 62.1 (55.3–68.4) 85.3 (79.9–89.6) 80.8 (75.0–85.7)
HIV positive (n= 167) 62.3 (53.1–70.9) 86.1 (78.6–91.7) 78.7 (70.4–85.6)
HIV negative (n= 54) 63.2 (46.0–78.2) 89.5 (75.2–97.1) 86.8 (71.9–95.6)
Speciﬁcity
Cohort (n = 306) 56.1 (44.7–67.0) 73.2 (62.2–82.4) 75.6 (64.9–84.4)
HIV positive (n= 167) 51.1 (35.8–66.3) 71.1 (55.7–83.6) 73.3 (58.1–85.4)
HIV negative (n= 54) 50.0 (24.7–75.3) 75.0 (47.6–92.7) 81.3 (54.4–96.0)
PPV
Cohort (n = 306) 79.4 (72.7–85.2) 89.7 (84.8–93.4) 90.0 (85.1–93.8)
HIV positive (n= 167) 77.6 (68.0–85.4) 89.0 (81.9–94.0) 88.9 (81.4–94.1)
HIV negative (n= 54) 75.0 (56.6–88.5) 89.5 (75.2–97.1) 91.7 (77.5–98.2)
NPV
Cohort (n = 306) 35.1 (27.0–43.9) 64.5 (53.9–74.2) 59.0 (49.0–68.5)
HIV positive (n= 167) 33.3 (22.4–45.7) 65.3 (50.4–78.3) 55.9 (42.4–68.8)
HIV negative (n= 54) 36.4 (17.2–59.3) 75.0 (47.6–92.7) 72.2 (46.5–90.3)
All values are in percentages (95% CI).based identiﬁcation (Patel et al., 2000) on negative cultures are also
recommended to eliminate the possibility of culture false-negatives.
The smear positive-culture positive group is associated with high
mycobacterial burden and most TB detection systems show high sensi-
tivity (94–100%) in this group. Sensitivities for GeneXpert and NWU-TB
in both subgroup and cohort analyses were within the reported ranges
of other molecular based systems in literature (Boehme et al., 2011;
Castan et al., 2014; Marlowe et al., 2011). However, in the problematic,
smear negative-culture positive group, NWU-TB showed a marginally
better sensitivity compared to GeneXpert in the subgroup and cohort
analyses. GeneXpert had a similar performance to that reported in an-
other South Africa study with a comparable HIV prevalence (Table 7)
(Scott et al., 2011). NWU-TB performed better (Table 7) than other mo-
lecular based MTB diagnosis in literature in the smear negative-culture
positive group.
Tuberculosis is a disease more commonly seen in developing coun-
tries and is typically associated with poverty. Although the GeneXpert
system is simple with good performance even in high HIV prevalence
settings, it's high costs ultimately leads to limited use (Helb et al.,
2010). In this study, the NWU-TB system shows comparable perfor-
mance to GeneXpert and due to the simplicity of the technology we es-
timate the cost per test to be less than US$4 compared to US$18 for
GeneXpert (Lawn and Nicol, 2011). One of the main advantages of the
NWU-TB system is the small sputum sample volume (250 μL) required
to obtain an accurate result compared to GeneXpert, which requires a
minimum volume of 0.7 mL (Boehme et al., 2010). This is beneﬁcial
for some patient populations such as the elderly, children, and HIV in-
fected individuals who have difﬁculties in expectorating sputum
(A. Harries et al., 1998; A.D. Harries et al., 1998; Zar et al., 2005). The
sputum sample matrix is also known for its complex PCR inhibitors,
and our ability to directly amplify (without need of a nucleic acid extrac-
tion step) lysed sputum samples with sensitivity comparable to that of
GeneXpert is signiﬁcant.
The total assay time (TAT) for NWU-TB system is about 1 h 30 min
consisting of a 7 minute cell lysis step, 25 min PCR cycling, 30 min
agarose gel processing and 30 min for manipulation procedures in be-
tween the steps. The semi-automation of the NWU-TB system is one
of the next steps in its development and this will further reduce TAT
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Fig. 4. Time to positivity after MGIT culture of NWU-TB system lysed 10-fold serial dilu-
tions ofM. tuberculosis over a period of 42 days.
Table 7
Reported diagnostic performance of different NAATs in smear-negative sputum TB presumptive individuals in different countries.
Location Test HIV prevalence Sensitivity % (95% CI) Reference
Brazil Gen-Probe A-MTD 100% 70.8 (48.0–87.3) Barreto et al. (2014)
Zambia Gen-Probe A-MTD 75% 60.0 (43.0–87.3) Kambashi et al. (2001)
Zambia IS6110 PCR 75% 40.0 (25.0–57.0) Kambashi et al. (2001)
South Africa GeneXpert 70% 61 Scott et al. (2011)
South Africa GeneXpert 75.3% 61. 5 This study
South Africa NWU-TB 75.3% 76.1 This study
42 I. Mutingwende et al. / Journal of Microbiological Methods 116 (2015) 37–43GeneXpert (2 h) will reduce patient dropout rates ensure timely initia-
tion of effective treatment for infected patients and timely quarantine of
infected individuals, which has a signiﬁcant role in controlling spread of
tuberculosis.
Potential dangers during mycobacterial culture are well known and
widely reported in literature (Bemer-Melchior and Drugeon, 1999;
Cruciani et al., 2004). For SSM, there is limited epidemiologic data
linking smear preparation with tuberculosis risk; however, most na-
tional guidelines recommend sputum handling and AFB smear prepara-
tion inside a biological safety cabinet (BSC) (Chedore et al., 2002; Kent,
1985). An ideal POC-TB test should carry less risk than SSM and should
aim to eliminate all infectious risk. Safety during lysis and handling of
lysates for health care workers is of primary concern and must be
thoroughly investigated before deployment of any system. There is con-
trasting evidence as to the efﬁciency of heat of inactivation of M. tuber-
culosis. For example, Zwadik et al. reported the occurrence of living
microorganisms after 30 min at 95 °C (Zwadyk et al., 1994). In NWU-
TB, rapid cell lysis is achieved through a combination of thermal, chem-
ical andmechanicalmeans (Grobler et al., 2012). The 7minute heat lysis
step of the NWU-TB system may point toward a biohazard risk due to
incomplete inactivation of the mycobacteria. However, the inclusion of
a chemical lysis buffer which weakens the bacterial cell wall enable
use of such a short lysis time as demonstrated by zero mycobacterial
growth after 42 days of MGIT culture in this preliminary study. The
LMR used for lysis is ﬁtted with a ﬁlter (Fig. 5) to trap bioaerosols
formed during heating at the high temperatures. Although smoke-
tests were performed, in-depth studies using a Biosampler to trap aero-
sols exiting the LMR ﬁlter during lysis step are needed before reaching
ﬁnal conclusion on the biosafety. From the preliminary assessment it
can be concluded that there is complete mycobacterial inactivation
after the 7 minute lysis step. Bacillary load has been reported to be
one of the main variables in causing incomplete mycobacteria inactiva-
tion but in this study there was complete inactivation independent of
the bacillary load (Castro et al., 2009).
In conclusion, the NWU-TB system has shown good sensitivity and
speciﬁcity results comparable to GeneXpert, which is the best in class
molecular based TB detection test. The system is also safe, and based
on a simple and efﬁcient sputum sample preparation method. Further
development of the NWU-TB system is ongoing.Filter
Fig. 5. Aerial view of LMR showing a ﬁtted ﬁlter to trap bioaerosols during heat lysis.5. Limitations of the study
Thepatient cohort does not represent the normal population and the
high accuracy reported in this study could be due to the high prevalence
of MTB strains with multiple copies of the insertion sequence IS6110 in
this cohort (Alonso et al., 2013). Fresh sputum samples were used for
GeneXpert, SSM and MGIT culture, but frozen samples stored for up to
a year were used for NWU-TB analysis. Association between the use of
frozen sputum samples and reduced the sensitivity of another
(GeneXpert) molecular test has been previously reported (Steingart
et al., 2013). The use of frozen samples may have altered the perfor-
mance of NWU-TB and future evaluation studies must include fresh
samples. Like all other current molecular based systems, our system
does not distinguish between live and dead mycobacteria, which
could partly explain the lower speciﬁcity especially in such a high TB
prevalence setting.
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